1. Joseph DJ et al. Ten year final results of the TROG 03.04 (RADAR) randomised phase 3 trial evaluating duration of androgen suppression ± zoledronic acid for locally advanced prostate cancer. ASCO-GU 2018, Abstract #1.
2. Ravi P et al. Prognostic factors in men receiving salvage androgen deprivation therapy for prostate cancer: Impact of absolute PSA and PSA doubling time. ASCO-GU 2018, Abstract #129.
3. Hussain M et al. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). ASCO-GU 2018, Abstract #3.
4. Small EJ et al. SPARTAN, a phase 3 double-blind, randomized study of apalutamide vs placebo in patients with nonmetastatic castration-resistant prostate cancer. ASCO-GU 2018, Abstract #161.
5. Lozano R et al. Comparative assessment of abiraterone and enzalutamid activity in the PROREPAIR-B study. ASCO-GU 2018, Abstract #164.
